CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

James R. Berenson(Oncotherapeutics (United States)), Jesús G. Berdeja(Tennessee Oncology), Janet L. Anderl(Amgen (United States)), Robert M. Rifkin(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Richy Agajanian(Oncology Institute of Hope and Innovation), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Morton Coleman(Cornell University), Alberto Bessudo(California Cancer Associates for Research and Excellence), Robert A. Moss(Valley Regional Hospital), Priti Patel(AstraZeneca (United States)), Wael A. Harb, Ying Ou(Hunan Normal University), Sandra Dixon(Amgen (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Alan Cartmell(Newcastle University), Sanjay Aggarwal(All India Institute of Medical Sciences), Roger M. Lyons(Hematology Oncology Associates)
Blood
May 13, 2016
10.1182/blood-2015-11-683854
Cited by 94

Related Papers

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795